Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect
Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of...
Gespeichert in:
Veröffentlicht in: | Carcinogenesis (New York) 2017-02, Vol.38 (2), p.134 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 2 |
container_start_page | 134 |
container_title | Carcinogenesis (New York) |
container_volume | 38 |
creator | Yang, Juan Wang, Cun Zhao, Fengbo Luo, Xiaoying Qin, Meilin Arunachalam, Einthavy Ge, Zhouhong Wang, Ning Deng, Xuan Jin, Guangzhi Cong, Wenming Qin, Wenxin |
description | Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC. |
doi_str_mv | 10.1093/carcin/bgw109 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_carcin_bgw109</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>27742690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-d564af5904de502d16b0bb3f97dc832cc42db6936c456a1f22d2a6e3337b16643</originalsourceid><addsrcrecordid>eNo9kM1OwzAQhC0EoqVw5Ir8AqH-i1MfoaKAFAkOII7R2lmnQSmpbAfE25MqwGk0q0-7O0PIJWfXnBm5dBBc-7G0zddoj8icK80ywVfsmMwZVzKTUqoZOYvxnTGuZW5OyUwUhRLasDlpyz5G2nu6uX3m1INruzZBwkihaQLG2H4i9QhpGM2B2-IeUu-w64YOAp3O9zugh1GkaRv6odmOivQNgh1CQ9F7dOmcnHjoIl786oK8bu5e1g9Z-XT_uL4pMyfNKmV1rhX43DBVY85EzbVl1kpvitqtpHBOidpqI7VTuQbuhagFaBxTFpZrreSCZNNeF8ZoAX21D-0OwnfFWXWorJp-rqbKRv5q4veD3WH9T_91JH8AnGhq4g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Yang, Juan ; Wang, Cun ; Zhao, Fengbo ; Luo, Xiaoying ; Qin, Meilin ; Arunachalam, Einthavy ; Ge, Zhouhong ; Wang, Ning ; Deng, Xuan ; Jin, Guangzhi ; Cong, Wenming ; Qin, Wenxin</creator><creatorcontrib>Yang, Juan ; Wang, Cun ; Zhao, Fengbo ; Luo, Xiaoying ; Qin, Meilin ; Arunachalam, Einthavy ; Ge, Zhouhong ; Wang, Ning ; Deng, Xuan ; Jin, Guangzhi ; Cong, Wenming ; Qin, Wenxin</creatorcontrib><description>Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC.</description><identifier>ISSN: 0143-3334</identifier><identifier>EISSN: 1460-2180</identifier><identifier>DOI: 10.1093/carcin/bgw109</identifier><identifier>PMID: 27742690</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - pathology ; Cell Proliferation - genetics ; Cell Transformation, Neoplastic - genetics ; Disease Progression ; DNA Helicases - antagonists & inhibitors ; DNA Helicases - genetics ; DNA-Binding Proteins - antagonists & inhibitors ; DNA-Binding Proteins - genetics ; Gene Expression Regulation, Neoplastic ; Gene Silencing ; Gluconeogenesis - drug effects ; Gluconeogenesis - genetics ; Hep G2 Cells ; Humans ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Liver Neoplasms - pathology ; Mice ; Naphthalenes - administration & dosage ; Neoplasm Metastasis ; Xenograft Model Antitumor Assays</subject><ispartof>Carcinogenesis (New York), 2017-02, Vol.38 (2), p.134</ispartof><rights>The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-d564af5904de502d16b0bb3f97dc832cc42db6936c456a1f22d2a6e3337b16643</citedby><cites>FETCH-LOGICAL-c398t-d564af5904de502d16b0bb3f97dc832cc42db6936c456a1f22d2a6e3337b16643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27742690$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Juan</creatorcontrib><creatorcontrib>Wang, Cun</creatorcontrib><creatorcontrib>Zhao, Fengbo</creatorcontrib><creatorcontrib>Luo, Xiaoying</creatorcontrib><creatorcontrib>Qin, Meilin</creatorcontrib><creatorcontrib>Arunachalam, Einthavy</creatorcontrib><creatorcontrib>Ge, Zhouhong</creatorcontrib><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Deng, Xuan</creatorcontrib><creatorcontrib>Jin, Guangzhi</creatorcontrib><creatorcontrib>Cong, Wenming</creatorcontrib><creatorcontrib>Qin, Wenxin</creatorcontrib><title>Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect</title><title>Carcinogenesis (New York)</title><addtitle>Carcinogenesis</addtitle><description>Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC.</description><subject>Animals</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cell Proliferation - genetics</subject><subject>Cell Transformation, Neoplastic - genetics</subject><subject>Disease Progression</subject><subject>DNA Helicases - antagonists & inhibitors</subject><subject>DNA Helicases - genetics</subject><subject>DNA-Binding Proteins - antagonists & inhibitors</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gene Silencing</subject><subject>Gluconeogenesis - drug effects</subject><subject>Gluconeogenesis - genetics</subject><subject>Hep G2 Cells</subject><subject>Humans</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - pathology</subject><subject>Mice</subject><subject>Naphthalenes - administration & dosage</subject><subject>Neoplasm Metastasis</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0143-3334</issn><issn>1460-2180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1OwzAQhC0EoqVw5Ir8AqH-i1MfoaKAFAkOII7R2lmnQSmpbAfE25MqwGk0q0-7O0PIJWfXnBm5dBBc-7G0zddoj8icK80ywVfsmMwZVzKTUqoZOYvxnTGuZW5OyUwUhRLasDlpyz5G2nu6uX3m1INruzZBwkihaQLG2H4i9QhpGM2B2-IeUu-w64YOAp3O9zugh1GkaRv6odmOivQNgh1CQ9F7dOmcnHjoIl786oK8bu5e1g9Z-XT_uL4pMyfNKmV1rhX43DBVY85EzbVl1kpvitqtpHBOidpqI7VTuQbuhagFaBxTFpZrreSCZNNeF8ZoAX21D-0OwnfFWXWorJp-rqbKRv5q4veD3WH9T_91JH8AnGhq4g</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Yang, Juan</creator><creator>Wang, Cun</creator><creator>Zhao, Fengbo</creator><creator>Luo, Xiaoying</creator><creator>Qin, Meilin</creator><creator>Arunachalam, Einthavy</creator><creator>Ge, Zhouhong</creator><creator>Wang, Ning</creator><creator>Deng, Xuan</creator><creator>Jin, Guangzhi</creator><creator>Cong, Wenming</creator><creator>Qin, Wenxin</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20170201</creationdate><title>Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect</title><author>Yang, Juan ; Wang, Cun ; Zhao, Fengbo ; Luo, Xiaoying ; Qin, Meilin ; Arunachalam, Einthavy ; Ge, Zhouhong ; Wang, Ning ; Deng, Xuan ; Jin, Guangzhi ; Cong, Wenming ; Qin, Wenxin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-d564af5904de502d16b0bb3f97dc832cc42db6936c456a1f22d2a6e3337b16643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cell Proliferation - genetics</topic><topic>Cell Transformation, Neoplastic - genetics</topic><topic>Disease Progression</topic><topic>DNA Helicases - antagonists & inhibitors</topic><topic>DNA Helicases - genetics</topic><topic>DNA-Binding Proteins - antagonists & inhibitors</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gene Silencing</topic><topic>Gluconeogenesis - drug effects</topic><topic>Gluconeogenesis - genetics</topic><topic>Hep G2 Cells</topic><topic>Humans</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - pathology</topic><topic>Mice</topic><topic>Naphthalenes - administration & dosage</topic><topic>Neoplasm Metastasis</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Juan</creatorcontrib><creatorcontrib>Wang, Cun</creatorcontrib><creatorcontrib>Zhao, Fengbo</creatorcontrib><creatorcontrib>Luo, Xiaoying</creatorcontrib><creatorcontrib>Qin, Meilin</creatorcontrib><creatorcontrib>Arunachalam, Einthavy</creatorcontrib><creatorcontrib>Ge, Zhouhong</creatorcontrib><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Deng, Xuan</creatorcontrib><creatorcontrib>Jin, Guangzhi</creatorcontrib><creatorcontrib>Cong, Wenming</creatorcontrib><creatorcontrib>Qin, Wenxin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Carcinogenesis (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Juan</au><au>Wang, Cun</au><au>Zhao, Fengbo</au><au>Luo, Xiaoying</au><au>Qin, Meilin</au><au>Arunachalam, Einthavy</au><au>Ge, Zhouhong</au><au>Wang, Ning</au><au>Deng, Xuan</au><au>Jin, Guangzhi</au><au>Cong, Wenming</au><au>Qin, Wenxin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect</atitle><jtitle>Carcinogenesis (New York)</jtitle><addtitle>Carcinogenesis</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>38</volume><issue>2</issue><spage>134</spage><pages>134-</pages><issn>0143-3334</issn><eissn>1460-2180</eissn><abstract>Reprogrammed metabolism has been identified as an emerging hallmark in cancer cells. It has been demonstrated that fructose-1, 6-bisphosphatase 1 (FBP1) as a rate-limiting enzyme in gluconeogenesis plays critical roles in tumor initiation and progression in several cancer types. However, function of FBP1 in hepatocellular carcinoma (HCC) is still not clear. In this study, we observed that the expression of FBP1 was obviously downregulated in the cell lines and tissues of HCC. Downregulation of FBP1 in HCC tissues was correlated with a lower overall survival rate and had a relatively higher tendency of tumor recurrence (n = 224). Silencing FBP1 could significantly promote colony formation, proliferation and metastasis of HCC cells, while ectopic overexpression of FBP1 resulted in impaired abilities of colony formation, proliferation and metastasis in vitro and in vivo. Mechanistically, silencing FBP1 facilitated glycolysis in HCC cell lines, which may be responsible for aggressiveness of HCC cells. We further found that targeting the Warburg effect using the specific inhibitor FX11 could suppress the aggressiveness of HCC cells which was mediated by loss of FBP1. These findings indicate that FBP1 appears to be a tumor suppressor in HCC. Strategies to restore the levels and activities of FBP1 might be developed to treat patients with HCC.</abstract><cop>England</cop><pmid>27742690</pmid><doi>10.1093/carcin/bgw109</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0143-3334 |
ispartof | Carcinogenesis (New York), 2017-02, Vol.38 (2), p.134 |
issn | 0143-3334 1460-2180 |
language | eng |
recordid | cdi_crossref_primary_10_1093_carcin_bgw109 |
source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Animals Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - pathology Cell Proliferation - genetics Cell Transformation, Neoplastic - genetics Disease Progression DNA Helicases - antagonists & inhibitors DNA Helicases - genetics DNA-Binding Proteins - antagonists & inhibitors DNA-Binding Proteins - genetics Gene Expression Regulation, Neoplastic Gene Silencing Gluconeogenesis - drug effects Gluconeogenesis - genetics Hep G2 Cells Humans Liver Neoplasms - drug therapy Liver Neoplasms - genetics Liver Neoplasms - pathology Mice Naphthalenes - administration & dosage Neoplasm Metastasis Xenograft Model Antitumor Assays |
title | Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A40%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Loss%20of%20FBP1%20facilitates%20aggressive%20features%20of%20hepatocellular%20carcinoma%20cells%20through%20the%20Warburg%20effect&rft.jtitle=Carcinogenesis%20(New%20York)&rft.au=Yang,%20Juan&rft.date=2017-02-01&rft.volume=38&rft.issue=2&rft.spage=134&rft.pages=134-&rft.issn=0143-3334&rft.eissn=1460-2180&rft_id=info:doi/10.1093/carcin/bgw109&rft_dat=%3Cpubmed_cross%3E27742690%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27742690&rfr_iscdi=true |